PLAN B (levonorgestrel) by Teva is demonstrated. First approved in 1999.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
Plan B (levonorgestrel) is an oral emergency contraceptive tablet approved in 1999 that prevents pregnancy through multiple mechanisms including cervical mucus thickening, sperm inhibition, and endometrial alteration. It is taken as a single dose following unprotected intercourse to prevent fertilization before implantation occurs. The drug represents a foundational over-the-counter option in reproductive health.
As LOE approaches, commercial teams will face margin compression and declining headcount; focus shifts to cost optimization and generic transition planning.
demonstrated. Studies of LNG-releasing IUSs suggest several mechanisms for pregnancy prevention: prevention of fertilization due to the thickening of the cervical mucus, which inhibits sperm passage through the cervix, and inhibition of sperm mobility and function (capacitation), and alteration of…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effects of Copper Versus Levonorgestrel Intrauterine Devices on Mucosal Microbiota and Barrier Function Among Young African Women
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on PLAN B at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Plan B offers limited career growth opportunities due to LOE status and zero linked job openings; roles available focus on managed decline, generic transition, and cost management rather than innovation or launch activities. Professionals seeking dynamic, growth-oriented assignments should consider alternate products with longer patent runways.